BioCentury
ARTICLE | Company News

Targacept, AstraZeneca deal

October 20, 2014 7:00 AM UTC

AstraZeneca ended an amended 2005 neurology deal with Targacept, which will regain all rights to compounds the biotech granted to the pharma, including AZD1446 (TC-6683). AZ said it ended the deal because preclinical studies did not support further development of AZD1446, which was also evaluated in Phase IIa trials for Alzheimer's disease and adult ADHD. Targacept said it has no "immediate" plans to continue development of the compounds. The biotech said it has received $88.1 million from AZ under the deal. ...